Health
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily in adult and adolescent patients living with non-segmental vitiligo (NSV).1 NSV, the most common form of vitiligo (occurring in over 90% of patients), is characterized by symmetrical and bilateral white patches on both sides of the body.2-4
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"In two replicate Phase 3 studies, upadacitinib (RINVOQ ® ) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial Vitiligo Area Scoring Index (F-VASI 75) from baseline at week 481","length":270,"tagName":"p"}]},{"val":[{"type":"text","content":"Both studies met key ranked secondary endpoints1","length":48,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":318,"olType":false},{"type":"text","content":"NORTH CHICAGO, Ill., Oct. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily in adult and adolescent patients living with non-segmental vitiligo (NSV).1 NSV, the most common form of vitiligo (occurring in over 90% of patients), is characterized by symmetrical and bilateral white patches on both sides of the body.2-4","length":470,"tagName":"p"},{"type":"text","content":""Vitiligo is more than a skin condition – it's a chronic autoimmune disease that can deeply affect a person's confidence, identity and daily life," said Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, AbbVie. "There are no approved systemic medical therapies for achieving re-pigmentation in vitiligo. These Phase 3 results represent a significant milestone in AbbVie's commitment to supporting patients and expanding our immunology portfolio to deliver innovative solutions."","length":591,"tagName":"p"},{"type":"text","content":"The Total Vitiligo Area Scoring Index (T-VASI) is a tool that measures the extent of de-pigmentation over the entire body while F-VASI measures de-pigmentation of the face, an area among the most visible and psychosocially impactful for people living with NSV. Across both studies approximately 70% of subjects had T-VASI > 10 at baseline. In both studies, upadacitinib achieved the co-primary endpoints of T-VASI 50 (≥50% reduction from baseline in T-VASI score) and F-VASI 75 (≥75% reduction from baseline in F-VASI score) at week 48 versus placebo. Across both studies, statistically significant differences were observed with upadacitinib versus place...